sameAs
Immunomodulatory interventions for focal epilepsy syndromesPharmacogenetics and pharmacogenomicsClinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 updateSLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalinkPossible interaction between warfarin and cranberry juiceEffect of topiramate on acid-base balance: extent, mechanism and effectsWarfarin: almost 60 years old and still causing problemsThe role of Clostridium difficile in the paediatric and neonatal gut - a narrative reviewNew genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivityThiopurine monitoring in children with inflammatory bowel disease: a systematic reviewInfluence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysisClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingPhenotype standardization for statin-induced myotoxicityProgress in pharmacogenetics: consortiums and new strategiesAdverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsCharacterization of the T-cell response in a patient with phenindione hypersensitivityHaemolytic anaemia associated with indinavirCarbamazepine is not a substrate for P-glycoproteinAntigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivoWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsDevelopment of the Liverpool Adverse Drug Reaction Avoidability Assessment ToolAdverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodesDevelopment and inter-rater reliability of the Liverpool adverse drug reaction causality assessment toolEnhancing communication about paediatric medicines: lessons from a qualitative study of parents' experiences of their child's suspected adverse drug reactionAdverse drug reactions causing admission to a paediatric hospitalA multi-system approach assessing the interaction of anticonvulsants with P-gpTelmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral thA genome-wide association study and biological pathway analysis of epilepsy prognosis in a prospective cohort of newly treated epilepsyHLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsyIncidence, characteristics and risk factors of adverse drug reactions in hospitalized children - a prospective observational cohort study of 6,601 admissions.Folate augmentation of treatment - evaluation for depression (FolATED): protocol of a randomised controlled trial.Integration of genetic, clinical, and INR data to refine warfarin dosing.Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometriesInvestigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome.Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.Genetic regulation of gene expression in the epileptic human hippocampus.Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy childrenDevelopment of ELISAs for diagnosis of acute typhoid fever in Nigerian children.Pharmacogenomics: Current State-of-the-Art
P50
Q24201788-AA9B847C-0BE4-4569-B174-18F9B985EF5DQ24564983-4A80E65D-411F-47FD-8978-31573F220ECFQ24567766-E328EF2A-4D00-42F7-811F-2C4C37C5C6EEQ24598793-15C38815-5EA9-496A-BFAF-7F27DF1EC63EQ24623457-261BD19D-AD98-444F-A0D1-A9752C055E09Q24643009-F3D3BD43-9E1F-4F1B-A10C-4ADD556507B6Q24678632-32D9795F-7425-47C3-BDBC-CDDB350F5CF9Q26750848-C86CD8B1-91FC-463B-8D69-201392E5B3B4Q26800976-B0AEEFB6-E573-4C52-8AFE-278B8EF207A8Q26859122-7A54A845-F7D1-4BF0-AF4D-46CE07DFE0A4Q27002899-216966F2-4CFE-4982-8DF4-084449E275BCQ27008360-7CFBDFC6-08F9-4A29-A50A-6EBDBF77664DQ27020935-7D5D4CE8-AE5A-48C5-8357-97C440B0A658Q28071652-7AE596E6-B91A-4F12-848D-B301C5858393Q28169189-D945872E-8507-474F-B213-2A407C3A5F37Q28237780-5E1EFC2E-2DD5-45E3-A37D-2F813F6B5998Q28343650-34D8FA78-6509-42E1-A6D9-2F8518CD6817Q28363548-CFBF3F12-5F00-4A12-A181-360CEEE345ADQ28364889-D7716920-D252-4A2A-A28D-A6E37913667BQ28395337-EFFE2D41-6D73-4049-841B-A9B2455A8B86Q28468439-DC44FCC8-9E5C-4420-BDD6-BA4881E46863Q28474740-160F3823-282D-4104-9EC3-DD36EE5E785AQ28478391-A79A3243-FB7A-4068-8025-71BE843EB800Q28484338-9301E38F-76C9-4E19-8895-0947E4E00E3FQ28485461-8DA6A73C-7646-4ECB-9812-9F72D4F7E031Q28533527-F2DE38A0-9586-4BA8-B320-C93087C2B001Q28610551-6503E8BE-0B73-47AB-AA2E-BE07562ED076Q28943418-6A3BB03F-D008-4167-A07C-0A51E5ADA73BQ29417159-BA304BC4-2F84-44AE-925C-B1DD644723C1Q30854108-51A7468D-10D7-4DF8-8209-BEF32CF037F4Q31143856-047298D3-BD71-4602-87D1-734DA66F9905Q33305713-756972E1-D9EF-479C-823F-0A08CDDE9D28Q33550741-A982A8BE-E3EE-4EEA-881E-91FDCA2B8DE7Q33574656-182C9604-86E4-4345-A90D-47D65E1B70A4Q33588629-B0D581C3-BE9F-477A-98E2-2680A27EF93EQ33589777-AE9C9965-F8CF-4B40-80A1-825829411630Q33622547-DDDE0F93-6849-476A-AEDE-FD1D35A76916Q33825429-EA643D7C-1BB4-415B-9307-03CDA2D488E1Q33874236-6F7D8DFC-F0A5-4BFF-81E2-1347D927A257Q33891714-DABD42DB-B663-4CAF-B2FB-965526E6314E
P50
description
British pharmacologist
@en
British pharmacologist
@en-ca
British pharmacologist
@en-gb
farmacoloog
@nl
farmacólogo británico
@es
عالم صيدلية بريطاني
@ar
name
Munir Pirmohamed
@af
Munir Pirmohamed
@an
Munir Pirmohamed
@ast
Munir Pirmohamed
@bar
Munir Pirmohamed
@br
Munir Pirmohamed
@ca
Munir Pirmohamed
@co
Munir Pirmohamed
@cs
Munir Pirmohamed
@cy
Munir Pirmohamed
@da
type
label
Munir Pirmohamed
@af
Munir Pirmohamed
@an
Munir Pirmohamed
@ast
Munir Pirmohamed
@bar
Munir Pirmohamed
@br
Munir Pirmohamed
@ca
Munir Pirmohamed
@co
Munir Pirmohamed
@cs
Munir Pirmohamed
@cy
Munir Pirmohamed
@da
prefLabel
Munir Pirmohamed
@af
Munir Pirmohamed
@an
Munir Pirmohamed
@ast
Munir Pirmohamed
@bar
Munir Pirmohamed
@br
Munir Pirmohamed
@ca
Munir Pirmohamed
@co
Munir Pirmohamed
@cs
Munir Pirmohamed
@cy
Munir Pirmohamed
@da
P214
P244
P268
P269
P1053
H-6004-2011
P106
P1153
7006669713
P1412
P21
P213
0000 0001 2424 9116
P214
P244
n2005089733
P268
P269
P2798
P31
P3829
P496
0000-0002-7534-7266
P5463
Pirmohamed_Munir
P569
1950-01-01T00:00:00Z
P7859
lccn-n2005089733